$TRUP

Tooth Margaret sold $26K of TRUP

Tooth Margaret (CEO) sold 1,000 shares of TRUPANION, INC. (TRUP) at $25.84 on 2026-10-09 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Tooth Margaret
Published Oct 13, 2026, 10:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 13, 2026, 10:13 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TRUP
Neutral
medium confidence
Mentioned
$TRUP
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TRUPNeutralLow
01

Why it matters

This provides incremental sentiment information about insider behavior but does not change company fundamentals or near-term expectations.

02

Market read

Traders may note the insider sale for sentiment, but the small dollar amount and 10b5-1 plan suggest limited tradable impact.

03

What to watch

The article does not indicate whether the CEO also bought shares, nor does it provide broader insider activity context beyond this single sale.

Relevance 2/10Novelty 2/10Timing: filed after-hours Oct. 13, reflecting the Oct. 9 sale

Background

The filing is an SEC Form 4 insider transaction for TRUP, reported as an open-market sale under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$TRUPNeutralMedium confidence
Context

TRUP insider Form 4 shows CEO Tooth Margaret sold 1,000 shares at $25.84 on a pre-arranged 10b5-1 plan, filed Oct. 13.

Expected impact

Shares may face slight overhead from the optics of an insider sale, though impact is likely limited given the pre-arranged 10b5-1 plan.

Evidence & confidence

The transaction is small ($25,840) and explicitly tied to a pre-arranged 10b5-1 plan, which typically dampens market interpretation versus discretionary selling.

Market effects

Minimal, as this is a routine, small-scale insider sale with no operational or guidance change.

None.

None.

Counterpoint

Because it is a pre-arranged 10b5-1 sale, the market may overreact; the filing can be largely noise for near-term price action.

Key entities

  • TRUPANION, INC.

    US-listed company whose CEO filed an SEC Form 4 for an insider sale under a 10b5-1 plan.

  • Tooth Margaret

    CEO and director who sold 1,000 shares at $25.8400 on Oct. 9, 2026.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$TRUPMedAI 8/10

Property & Casualty Insurance Stocks Q2 Results: Benchmarking Trupanion (NASDAQ:TRUP)

Essent Group (ESNT) reported Q2 revenues of $362.7M, up 13.6% YoY, beating estimates. Radian Group (RDN) reported $580.7M in revenues, up 95.7% YoY, but missed EPS estimates. Fidelity National Financial (FNF) reported $4.05B in revenues, up 11.4% YoY, beating estimates. W. R. Berkley (WRB) reported $3.72B in revenues, up 1.2% YoY, missing revenue estimates but beating EPS estimates.

$TRUPMed

Why Trupanion (TRUP) Shares Are Sliding Today

Trupanion (TRUP) shares fell 5.8% after Piper Sandler downgraded the stock to Neutral, citing challenges in the pet insurance market and rising claim costs. The firm lowered its price target to $32 from $45. The stock has seen significant volatility, down 19.6% year-to-date and 35.6% from its 52-week high.

$TRUPHigh

Why is Trupanion stock sliding today?

Trupanion stock fell 6.4% after Piper Sandler downgraded it to Neutral and cut its price target to $32 from $45, citing revenue and margin pressures. Zacks Research also downgraded the stock, amplifying the selloff. The company's shares have retreated from their 52-week high of $46.98, trading near the 52-week low of $21.16.

$TRUPMed

Trupanion (TRUP) Is Up 13.4% After New Vet Partnerships and Q2 Results - Has The Bull Case Changed?

Trupanion reported Q2 2026 results with net income of $6.83 million and updated revenue guidance, and it announced new partnerships and integrations with Digitail and Home To Home. The article links VetDirect Pay and Exam Day coverage to pet-care workflows and discusses margin and subscription growth targets, including projected $2.0 billion revenue and $36.5 million earnings by 2029.

$METMed

Financial results round-up: MetLife, Prudential, Corebridge, Palomar, Heritage, TWFG, Root and more

A financial results roundup covers multiple insurers and MGAs. MetLife reported Q2 net income of $705m and adjusted EPS $2.43. Prudential posted Q2 net income of $985m and record individual life sales. Corebridge reported a $16m net loss and merger approval. Palomar, Heritage, TWFG, Root, Trupanion and Clover Health also reported Q2 figures and guidance updates.